MARKETS / NASDAQ / COO

NASDAQ · OPHTHALMIC GOODS · LARGE CAP

Cooper Companies, Inc. COO

18 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$4.1B

▲ 5.1% YoY

Net income

$374.9M

▼ 4.4% YoY

Free cash flow

$433.7M

▲ 50.5% YoY

In brief

What this company does

The Cooper Companies, Inc. provides products and services in the fields of vision, fertility, and women's health. Headquartered in San Ramon, California, it sells products in over 130 countries. As of October 31, 2025, it had a workforce of more than 15,000. Cooper operates through two business segments, CooperVision and CooperSurgical. CooperVision provides products for contact lens wearers, developing, manufacturing, and marketing a broad range of single-use, two-week, and monthly contact lenses featuring advanced materials and optics. CooperSurgical's medical devices are used in gynecology and obstetrics, including surgical products, contraception, and labor and delivery, as well as cord blood and cord tissue storage services, while its fertility portfolio encompasses medical devices supporting the in vitro fertilization process, egg and sperm donation, cryopreservation, and genomic services. Since its inception in 1990, CooperSurgical has established its market presence and distribution system by developing products and acquiring products and companies that complement its business model.

Written from the business description in COOPER COMPANIES, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 5 December 2025. Every sentence was checked against that document before publication.

Growth

USD 4.1B

Revenue, FY2025 · full 18-year series below

Revenue $B Net income $B

FY2025 · Revenue 4.1 · Net income 0.4

Compound annual growth

Revenue

+7.3%

+11.0%

+8.6%

+8.8%

Net income

−1.0%

+9.5%

+6.3%

+8.3%

Returned to shareholders

+52.7%

+41.7%

+15.2%

+36.5%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +11.0% a year over five years — but profit grew slower: net income at +9.5%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

9 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 16.7% · Net 9.2%

ROE

FY2025 · ROE 4.6%

Gross margin65.5%

Operating margin16.7%

Net margin9.2%

Return on assets3.0%

EBITDAUSD 1.1B

Each USD of equity produced 5 cents of profit this year.

Cash & shareholders

USD 290.1M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 433.7

Net buybacks $M Dividends $M

FY2025 · Dividends 0.0 · Net buybacks 290.1

Dividends paid—

Net buybacksUSD 290.1M

Share of profit77.4%

Consecutive raises—

USD 290.1M in buybacks — 77% of the year's profit went back to shareholders.

Total assetsUSD 12.4B

EquityUSD 8.2B

CashUSD 110.6M

Gross debtUSD 2.5B

Net debtUSD 2.4B

Current ratio1.89×

Net debt stands at 29% of equity.

The 18-year record

18 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue $B	4.1	3.9	3.6	3.3	2.9	2.4	2.7	2.5	2.1	2.0	1.8	1.7	1.6	1.4	1.3	1.2	1.1	1.0
Operating income $B	0.7	0.7	0.5	0.5	0.5	0.3	0.5	0.4	0.4	0.3	0.2	0.3	0.3	0.3	0.2	0.2	0.1	0.1
EBITDA $B	1.1	1.1	0.9	0.9	0.8	0.5	0.7	0.5	0.6	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.2	0.2
Income tax $B	0.2	0.2	0.1	0.1	−2.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income $B	0.4	0.4	0.3	0.4	2.9	0.2	0.5	0.1	0.4	0.3	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1
Free cash flow $B	0.4	0.3	0.2	0.5	0.5	0.2	0.4	0.5	0.5	0.4	0.1	0.2	0.2	0.2	0.2	0.2	0.1	−0.0
EPS, diluted $	1.87	1.96	1.48	1.94	59.16	4.81	9.33	2.81	7.52	5.59	4.14	5.51	5.96	5.05	3.63	2.43	2.21	1.42
Dividend / sh $	·	·	0.01	0.01	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	·	·	·	·
Payout %	0	0	1	1	0	1	1	2	1	1	1	1	1	1	2	2	3	4
ROE %	4.6	5.0	4.0	5.5	54.7	6.4	13.5	4.3	12.7	10.2	7.8	10.8	12.9	12.0	9.7	7.0	6.8	4.5
Shares out B	0.20	0.20	0.20	0.05	0.05	0.05	·	·	·	·	·	·	·	·	·	·	·	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityOphthalmic Goods

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsOctober 31

Data on record since2008